The Global Peptide Therapeutics Market is Predict to reach $58.4 Billion by 2028, at a CAGR of 6.3%

30-Jun-2022 | Report Format: Electronic (PDF)

Peptide Therapeutics Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Peptide Therapeutics Market size is expected to reach $58.4 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.

The Generic segment is showcasing a CAGR of 8% during (2022 - 2028). Generic medicine adoption is estimated to be driven by rising healthcare prices and greater federal government healthcare spending. The lapse of patents on several branded pharmaceuticals is also seen to be a major force behind the growth of the generic segment. Patent expiration is seen as a huge opportunity for generic companies to join the market offering a low-cost alternative to breakthrough pharmaceuticals.

The Parenteral Route segment acquired maximum revenue share in the Global Peptide Therapeutics Market by Route of Administration in 2021, thereby, achieving a market value of $43.7 billion by 2028. This can be ascribed to the high adoption rate, speedier medicine delivery, and ease of use. The biopharmaceutical monoliths are always looking for novel ways to deliver drugs that are relevant to peptides. Engineered compounds with improved PEGylation are presently being tested for efficacy in an attempt to increase medication delivery performance as well as patient compliance via better mechanisms of drug delivery.

The Solid Phase Peptide Synthesis (SPPS) segment has shown growth rate of 6.7% during (2022 - 2028). The rising growth of the segment is attributed to the fact that SPPS reduces synthesis time and is employed in a variety of manufacturing processes. Furthermore, increased efficiency during the production of longer peptides is a key driver. Moreover, the market is likely to be driven by associated automation, scalability, and improved control over the physicochemical features of peptides over the forecast period.

The In-house segment is leading the Global Peptide Therapeutics Market by Type of Manufacturers in 2021, thereby, achieving a market value of $37.8 billion by 2028. Due to rigorous regulations along with the high expense of outsourcing, most of the major businesses are researching peptide therapies in-house. Large pharmaceutical businesses choose in-house manufacturing because they have the necessary infrastructure and sophisticated technologies for large-scale production.

The Cardiovascular Disorder segment is experiencing a CAGR of 6.9% during (2022 - 2028). The growth of the segment in owing to the rise in the number of cardiovascular disorders all over the world. There is a rise in the mortality rate of cardiovascular disorders in the recent years. Major factors that are contributing to the surge in the incidences of these diseases and disorders are constantly declining air quality, increasing cases of obesity, and a rise in the worldwide geriatric population. Therefore, the growth of this segment is continuously rising.

The North America market dominated the Global Peptide Therapeutics Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $23.5 billion by 2028. The Europe market is estimated to witness a CAGR of 5.6% during (2022 - 2028). Additionally, The Asia Pacific market would experience a CAGR of 7.3% during (2022 - 2028).

Full Report:

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Eli Lilly And Company, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Lonza Group AG, and Amgen, Inc.

Global Peptide Therapeutics Market Segmentation

By Type

  • Innovative
  • Generic

By Route of Administration

  • Parenteral Route
  • Pulmonary
  • Mucosal
  • Oral Route
  • Others

By Synthesis Technology

  • Liquid Phase Peptide Synthesis (LPPS)
  • Solid Phase Peptide Synthesis (SPPS)
  • Hybrid Technology

By Type of Manufacturers

  • In-house
  • Outsourced

By Application

  • Metabolic
  • Cardiovascular Disorder
  • GIT & Renal
  • Antiinfection & Dermatology
  • Respiratory
  • Central Nervous System
  • Cancer
  • Pain
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Eli Lilly And Company
  • AstraZeneca PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical Company Limited
  • Lonza Group AG
  • Amgen, Inc.


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities


Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities


Call: +1(646) 600-5072

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale